About Matt Haywood

A pharmaceutical leader with nearly 30 years of industry experience, Matt brings a broad perspective across markets and across the portfolio and asset lifecycle, spanning sales, managed care, policy and advocacy, brand marketing, payer strategy, and global market access. His experience includes both U.S. and international markets, with particularly deep expertise in oncology and hematology, China, Japan, and the complex reimbursement environments that shape access around the world.

Matt began his career at Bristol Myers Squibb in field-based commercial roles, progressing from sales and hospital accounts into sales leadership, managed care, and policy advocacy before moving into payer marketing, HCP marketing, and brand leadership. He eventually returned to market access to lead work within BMS’s hematology franchise before joining AbbVie to help build its oncology market access capabilities and deepen his international experience. Over nearly a decade at AbbVie, Matt took on increasingly senior global and regional roles, ultimately serving as Vice President of International Market Access and Pricing for Oncology, with responsibility spanning more than 40 markets.

Throughout his career, Matt has worked well upstream of launch, helping shape the decisions that ultimately determine an asset’s value and access potential. His experience includes:

  • portfolio strategy and investment prioritization,

  • optimizing clinical endpoints to demonstrate value

  • leading indication sequencing for a hematology asset

  • developing accelerated launch and reimbursement strategies across international markets

  • led three successful China NRDL listings generating significant increases in peak sales

  • developed a Japan pricing strategy that shifted comparisons away from older technologies to more than double the price

  • led expansion of an oncology medicine to more than 50 countries

His work led to accelerated reimbursement across many key markets, as well as building and leading market access organizations across major international regions.

Matt describes his work as finding the “possibilities between patient and profit.” He believes the strongest strategic choices come from understanding the full picture—the customer, the asset, the market, and the broader portfolio—and using that breadth to uncover new ways to create sustainable value for both patients and shareholders.

A Perspective Across the Landscape

My experience has given me the opportunity to see pharmaceutical decisions from many different perspectives: across markets, functions, portfolios and the asset lifecycle. I have worked from early asset and evidence choices through pricing, reimbursement, launch and lifecycle management, and across markets ranging from the U.S. and major developed countries to China and broader international markets.

That breadth matters because important opportunities rarely sit neatly within one function, market or point in time. A development choice can create an access opportunity. A market insight can change an asset strategy. A portfolio decision can make an opportunity worth pursuing that might not make sense for an asset on its own. Seeing more of the landscape makes it possible to recognize those connections earlier and make better choices about where to invest.

That perspective is at the heart of HaywoodMAP: see more, connect more, and use those connections to create greater value for patients and shareholders.

Why HaywoodMAP

The name HaywoodMAP has a personal meaning for me as well. My father was a cartographer, and maps and geography were part of my life long before I began working in market access. We shared a fascination with geography in many forms, from the fault-block topography of the American West and the wilderness of Alaska to national parks and unusual geographic phenomena like tidal bores. We were fascinated not only by the places themselves, but by understanding the forces that shaped them and how those forces could sometimes come together to create something unexpected.

Maps were often part of how we explored and understood those places together. I have come to see a connection between that perspective and the work I have done throughout my career. A good map does more than show you where things are. It helps you understand the landscape, see relationships that may not be obvious and recognize different paths to a destination. I think the same is true when making difficult choices about an innovative medicine.

MAP stands for Market Access Partners, but it also reflects how I approach the work: understand the broader landscape, connect what might otherwise be viewed separately, and find a path that creates new possibilities.

Start a Conversation

Have an asset, market or portfolio question where the path forward isn't obvious?

HaywoodMAP works with biotech and pharmaceutical leaders on complex choices across markets and across the portfolio and asset lifecycle.

Let's explore what might be possible.